Last reviewed · How we verify
Plasma HPV
At a glance
| Generic name | Plasma HPV |
|---|---|
| Sponsor | Sunnybrook Health Sciences Centre |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines (PHASE4)
- Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma (PHASE2)
- Using Plasma Human Papillomavirus (HPV)-Related Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA) to Follow Response of Cervical Cancer to Surgery, Radiation, and Chemotherapy
- Non-Invasive Plasma Treatment for Cervical Infections: Targeting High- and Low-Risk HPV Variants
- BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients (PHASE2)
- Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma (PHASE2)
- Assessing the Utility of Plasma ctHPVDNA for Anal Cancer Screening
- Circulating Human Papilloma Virus (HPV) DNA for the Screening and Surveillance of Gynecologic Cancers (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Plasma HPV CI brief — competitive landscape report
- Plasma HPV updates RSS · CI watch RSS
- Sunnybrook Health Sciences Centre portfolio CI